Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

In the trials, tirzepatide (Mounjaro, Eli Lilly) was associated with a mean weight loss of about 26% in both trials, with a safety profile similar to that previously reported in other SURMOUNT ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Eli Lilly’s trending weight loss candidate tirzepatide has scored its second pivotal trial win—once again with impressive results.. Also known as Mounjaro when marketed as a Type 2 diabetes ...

The tirzepatide group had more injection-site reactions than the semaglutide group, which is consistent with other SURMOUNT trials. 14,20 In the current trial, no participants were reported to ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and ...